Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) - Analysts at KeyCorp issued their FY2026 EPS estimates for shares of Castle Biosciences in a report released on Thursday, November 5th. KeyCorp analyst P. Knight expects that the company will post earnings per share of ($0.82) for the year. KeyCorp currently has an "Overweight" rating and a $40.00 target price on the stock. The consensus estimate for Castle Biosciences' current full-year earnings is ($0.82) per share. KeyCorp also issued estimates for Castle Biosciences' Q4 2026 earnings at ($0.14) EPS and FY2027 earnings at ($0.11) EPS.
A number of other brokerages also recently issued reports on CSTL. Wall Street Zen raised Castle Biosciences from a "hold" rating to a "buy" rating in a report on Sunday, November 1st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Castle Biosciences in a report on Thursday, October 29th. Mizuho began coverage on Castle Biosciences in a research report on Thursday, October 29th. They set an "outperform" rating and a $60.00 target price on the stock. Robert W. Baird boosted their target price on Castle Biosciences from $39.00 to $41.00 and gave the stock an "outperform" rating in a research note on Monday, November 9th. Finally, BTIG Research boosted their target price on Castle Biosciences from $44.00 to $52.00 and gave the stock a "buy" rating in a research note on Monday, November 9th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $46.50.
Check Out Our Latest Analysis on Castle Biosciences
Castle Biosciences Price Performance
Castle Biosciences stock opened at $33.79 on Monday. Castle Biosciences has a 1-year low of $17.72 and a 1-year high of $44.28. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.28 and a quick ratio of 5.12. The stock has a market cap of $1.04 billion, a PE ratio of -43.88 and a beta of 1.00. The stock's fifty day moving average is $34.35 and its two-hundred day moving average is $28.33.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.22. The firm had revenue of $101.95 million during the quarter, compared to the consensus estimate of $92.76 million. Castle Biosciences had a negative net margin of 6.10% and a negative return on equity of 4.89%.
Insiders Place Their Bets
In other news, insider Tobin Juvenal sold 9,050 shares of Castle Biosciences stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $35.04, for a total transaction of $317,112.00. Following the sale, the insider owned 66,914 shares in the company, valued at approximately $2,344,666.56. The trade was a 11.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Derek J. Maetzold sold 12,428 shares of Castle Biosciences stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $33.20, for a total value of $412,609.60. Following the sale, the insider owned 21,479 shares in the company, valued at $713,102.80. This trade represents a 36.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 132,300 shares of company stock valued at $4,531,018. 6.10% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in CSTL. BlackRock Inc. purchased a new stake in Castle Biosciences in the second quarter valued at approximately $78,513,000. Jefferies Financial Group Inc. acquired a new stake in shares of Castle Biosciences in the second quarter valued at approximately $15,440,000. Renaissance Technologies LLC boosted its holdings in shares of Castle Biosciences by 8.1% in the first quarter. Renaissance Technologies LLC now owns 532,800 shares of the company's stock valued at $13,080,000 after acquiring an additional 39,700 shares during the period. AIGH Capital Management LLC purchased a new position in shares of Castle Biosciences during the second quarter worth approximately $13,001,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Castle Biosciences during the second quarter worth approximately $7,912,000. Hedge funds and other institutional investors own 92.60% of the company's stock.
About Castle Biosciences
(
Get Free Report)
Castle Biosciences, Inc. is a molecular diagnostics company that develops and commercializes tests intended to help physicians make personalized treatment and care decisions. Its tests analyze biological features of tissue to provide information about disease behavior and patient risk. The company's portfolio includes DecisionDx tests for conditions such as cutaneous melanoma, cutaneous squamous cell carcinoma and uveal melanoma. It also offers TissueCypher, a test designed to assess progression risk in patients with Barrett's esophagus.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Castle Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Castle Biosciences wasn't on the list.
While Castle Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.